Clinical Trials

Text Size A A

E-Mail to a Friend

secret  Click to Play Audio

Phase 1 Clinical Trials Program

The Phase 1 Clinical Trials Program at Seattle Cancer Care Alliance (SCCA) is the Pacific Northwest’s first academic-based program of its kind, serving Fred Hutchinson Cancer Research Center and the University of Washington Cancer Consortium.

photo of clinical trials unitThe mission of the program is to provide a centralized core of expertise for the conduct of first-in-human trials of investigational cancer therapeutic agents. Because conventional therapy is often ineffective for patients with advanced disease, the Phase I program offers innovative new agents for patients who have exhausted other treatment options. Potentially speeding the development of new therapies, these trials require a high level of technical and scientific competencies, like those found at SCCA. The program provides unique opportunities for correlative studies that take advantage of consortium research strengths such as world-class PET imaging, proteomics, biomarkers, and genomics cores.

Program Capabilities

The Phase 1 program is committed to providing a full range of research services to facilitate the development, implementation, and successful completion of clinical trials.

The majority of trials conducted are industry-sponsored. Typical study start-up time for opening a new trial is approximately 90 days. The regulatory review includes scientific board review and internal review board approval. Our program has experience in conducting outpatient (at SCCA) and inpatient trials (at University of Washington Medical Center).

Examples of new treatments being tested in the Phase 1 Program include immunemodulating therapies, targeted therapies, angiogenesis inhibitors, and cytotoxic agents for hematologic and solid tumor cancers.

Phase 1 Program trials are located on the web at:

Clinical Trials Unit

A brand new, dedicated Clinical Trials Unit (CTU) at SCCA is available for patients participating in Phase 1 trials. The new unit includes a nursing station, space for research coordinators, and four rooms where research subjects receive medications and undergo blood draws and other tests. The Patient Chair

Lounge is an adjacent open monitoring space where patients may receive oral drug and continued observation and sample collection. The Lounge features comfortable chairs, flat-panel television and snacks to create a pleasant environment for the patient. The unit operating hours are currently 8 a.m. to 10 p.m., Monday-Friday. If required by the protocol, overnight stays take place at University of Washington Medical Center. The dedicated PK processing lab and Investigational Drug Services are located in close proximity to the CTU.


Our program consists of highly skilled and dedicated staff, nurses and physicians who have extensive research experience and provide the exacting care and attention required to achieve potential breakthrough therapies.

John A. Thompson, MD, Director, Phase I Clinical Trials Program, Clinical Research Division, Member, Fred Hutchinson Cancer Research Center, University of Washington Professor, Medical Oncology Division

Laura Q. Chow, MD, Assistant Director, Phase I Clinical Trials Program, Clinical Research Division, Member, Fred Hutchinson Cancer Research Center, University of Washington Professor, Medical Oncology Division

Martin A. “Mac” Cheever, MD, Director, Solid Tumor Program, Fred Hutchinson Cancer Research Center, University of Washington Professor, Medical Oncology Division

Bojana I. Askovich, PhD,  Phase I Program Administrator

Research Team

Clinical Research Group

  • Audrey Mesher, CCRC Research Manager
  • Erica Peters, CCRC, Research Coordinator
  • Tara Davidson, Research Coordinator
  • Taylor Hain,  CCRC Research Coordinator
  • Hannah Lee, Research Coordinator 
  • Nam Nguyen, Research Coordinator 
  • Dana Snyder, Research Coordinator 
  • Sarah Trumbo, Research Coordinator
  • Jeniece Toro, Research Data Manager
  • Evan Hilsenberg, Data Coordinator
  • Audrey Merz, Data Coordinator
  • Rekha Ravindran, Data Coordinator
  • Adam Burton, Data Coordinator 
  • Laura Lockshon, Research Assistant

Regulatory Affairs

  • Reina Hibbert, CCRC, Regulatory Affairs Manager
  • Bran LeFae, Regulatory Coordinator

Financials/Administrative Support

  • Elsa Binag, CRCP, Budget and Contract Manager
  • Anna Liwanag, Budget/Fiscal
  • Leta Kao, Fiscal Specialist 1 


  • Shailender Bhatia, MD (melanoma, renal cancer)
  • Gabi Chiorian, MD (GI cancer)
  • Laura Chow, MD (head, neck and lung cancer)
  • Andrew Coveler, MD (GI cancer)
  • Ajay Gopal, MD (hematology)
  • Sunil Hingorani, MD, PhD (pancreas cancer)
  • Robin Jones, MD (sarcoma)
  • Eve Rodler, MD (breast cancer, sarcoma)
  • Jennifer Specht, MD (breast cancer)
  • Scott Tykodi, MD, PhD (melanoma, renal cancer)

Phase 1 Mid-Levels

Other contributors 

  • Sharol Bohl, RN, BSN
  • Barbara Jagels, MHA, RN, OCN
  • Barb Berg, PhD
  • Susan Hammond
  • Sonja Stella

CTU staff

Phase I Program
825 Eastlake Ave. E.
Mailstop G4-830
Seattle, WA 98109-1023
(206) 288-7551
Fax: (206) 288-6681